복합부위 통증 증후군(CRPS) 시장 전망 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Complex Regional Pain Syndrome (CRPS) Market was valued at USD 109 million in 2023 and is projected to grow at a CAGR of 2.4% from 2024 to 2032. Growth in this market is largely driven by the advancements in diagnostic technologies, rising prevalence of chronic pain conditions, and an increasing focus on personalized treatment approaches.

Pharmaceutical and biotechnology companies are actively developing CRPS-specific therapies aimed at reducing the duration and severity of symptoms. Cutting-edge diagnostic technologies enable earlier and more accurate identification of CRPS, leading to faster interventions and improved outcomes. Non-invasive diagnostic imaging and targeted pharmacological treatments are becoming more prevalent, allowing for a personalized approach that addresses each patient's unique condition and pain profile.

The CRPS market is segmented by disease type into CRPS I, CRPS II, and CRPS-NOS, with CRPS I, also known as Reflex Sympathetic Dystrophy, accounting for a significant share of USD 91.2 million in 2023. Representing approximately 90% of CRPS cases, CRPS I occurs following an injury or illness without direct nerve damage to the affected area. Growing awareness and advancements in diagnostics are spurring demand for effective treatments, further propelling market growth.

In terms of treatment type, the market is divided into medication and therapy, with the medication segment holding a substantial share of 66.1% in 2023. Medications are essential for pain relief and symptom management, improving the quality of life for CRPS patients. Commonly used drugs include NSAIDs, corticosteroids, anticonvulsants, and bisphosphonates. Additionally, advancements in pharmacological treatments, including new drug classes and nerve block techniques, are expanding options and driving improved patient outcomes.

The U.S. complex regional pain syndrome market is expected to grow at a CAGR of 2.3%, reaching USD 49.8 million by 2032. Factors contributing to this growth include a high prevalence of chronic pain conditions, robust healthcare infrastructure, and increasing rates of surgeries and accidental injuries. Furthermore, substantial investment in research is fostering innovation in pain management, particularly through neurostimulation and targeted treatments. Government initiatives in the U.S. also support market expansion by promoting improved pain management practices and efforts to reduce opioid dependence, advancing CRPS treatment options in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of CRPS
    • 3.2.1.2 Advancements in pain management therapies
    • 3.2.1.3 Rising awareness and diagnosis rates
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Potential side effects of available therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Disease Type, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 CRPS I
• 5.3 CRPS II
• 5.4 CRPS-NOS

Chapter 6 Market Estimates & Forecast, By Treatment, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Medication
  • 6.2.1 Analgesics
  • 6.2.2 Antidepressants
  • 6.2.3 Corticosteroids
  • 6.2.4 Opioids
  • 6.2.5 Other medications
• 6.3 Therapy
  • 6.3.1 Physical therapy
  • 6.3.2 Intrathecal drug pump
  • 6.3.3 Spinal cord stimulation
  • 6.3.4 Surgical sympathectomy
  • 6.3.5 Other therapies

Chapter 7 Market Estimates & Forecast, By Route of Administration, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Other routes of administration

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie
• 10.3 Averitas Pharma
• 10.4 Boston Scientific
• 10.5 Collegium Pharmaceutical
• 10.6 Eli Lilly and Company
• 10.7 Mallinckrodt Pharmaceuticals
• 10.8 Medtronic
• 10.9 Nevro
• 10.10 Pfizer
• 10.11 Sandoz
• 10.12 Teva Pharmaceutical